
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) – Equities research analysts at KeyCorp issued their Q1 2027 earnings per share (EPS) estimates for Maravai LifeSciences in a research note issued on Wednesday, November 11th. KeyCorp analyst P. Knight anticipates that the company will post earnings of $0.00 per share for the quarter. KeyCorp currently has an “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Maravai LifeSciences’ current full-year earnings is ($0.16) per share. KeyCorp also issued estimates for Maravai LifeSciences’ Q2 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.13) EPS.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business had revenue of $45.85 million during the quarter, compared to the consensus estimate of $43.56 million. Maravai LifeSciences had a negative return on equity of 12.44% and a negative net margin of 30.83%.
View Our Latest Stock Analysis on MRVI
Maravai LifeSciences Trading Down 1.9%
NASDAQ:MRVI opened at $7.40 on Tuesday. The company has a market capitalization of $1.92 billion, a PE ratio of -17.21 and a beta of 0.61. Maravai LifeSciences has a 52-week low of $2.80 and a 52-week high of $9.42. The stock’s 50 day moving average price is $7.40 and its 200 day moving average price is $5.44. The company has a quick ratio of 2.98, a current ratio of 4.66 and a debt-to-equity ratio of 0.51.
Hedge Funds Weigh In On Maravai LifeSciences
Several institutional investors have recently added to or reduced their stakes in MRVI. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Maravai LifeSciences in the third quarter valued at about $5,259,000. Marshall Wace LLP boosted its stake in shares of Maravai LifeSciences by 38.2% during the 3rd quarter. Marshall Wace LLP now owns 2,034,070 shares of the company’s stock worth $15,581,000 after acquiring an additional 562,593 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Maravai LifeSciences by 64.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock worth $4,015,000 after acquiring an additional 558,050 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Maravai LifeSciences by 24.5% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,043,668 shares of the company’s stock worth $15,654,000 after acquiring an additional 402,371 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Maravai LifeSciences in the 2nd quarter worth approximately $2,230,000. Institutional investors and hedge funds own 50.25% of the company’s stock.
About Maravai LifeSciences
Maravai LifeSciences provides products and services used by biotechnology and pharmaceutical companies in the development and production of therapeutics, vaccines, and other biologic products. Its offerings include specialized nucleic acid materials and analytical testing services that support research, manufacturing, and quality control. Through TriLink BioTechnologies, the company supplies modified nucleotides, custom RNA and DNA, and related materials used in applications such as messenger RNA research and production.
Recommended Stories
- Five stocks we like better than Maravai LifeSciences
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
